Background and purpose: Ischemic stroke activates Toll-like receptors (TLRs), triggering rapid inflammatory cytokine production. Axl signaling has multiple roles, including regulating cytokine secretion, clearing apoptotic cells, and maintaining cell survival, however, its role in inflammation after ischemic stroke has not been examined. We hypothesized that activation of Axl by recombinant Growth-arrest-specific protein 6 (rGas6) attenuates neuroinflammation by inhibiting the TLR/TRAF/NF-κB pathway after middle cerebral artery occlusion (MCAO) in rats. Meth: Sprague-Dawley rats were subjected to 2 h of MCAO. One hour after reperfusion, the rats were given an intranasal injection of rGas6, vehicle, or R428 (Axl receptor inhibitor). Neurological scores, infarct volumes, immunofluorescence staining, Morris Water Maze, rotarod test and histology alterations were analyzed. The expressions of proinflammatory cytokines, including IL-1β, IL-6, TNF-α, and Gas6, Axl, STAT1, SOCS1, SOCS3 and the TLR/TRAF/NF-κB pathway were quantified using Western blot. Results: Endogenous expressions of Gas6 and Axl decreased significantly by 24 h after MCAO. rGas6 reduced brain infarction and improved neurologic deficits scores, and increased expression of Axl and decreased the expressions of TRAF3, TRAF6 and inflammatory factors IL-1β, IL-6, and TNF-α. Four weeks after MCAO, rGas6 improved long-term neurological behavior and memory. Inhibition of the Axl/TLR/TRAF/NF-κB pathway reversed the brain protection by rGas6. Conclusion: rGas6 reduced the neurological deficits by inhibiting neuroinflammation via the TLR/TRAF/NF-κB signaling pathway. rGas6 can be used as potential treatment to ischemic stroke.
Introduction
Ischemic stroke, a devastating neurological disease, is the third leading cause of mortality and morbidity worldwide (Lakhan et al., 2009) . Following brain ischemia, microglia and astrocytes are activated via Toll-like receptors (TLRs) (Liu et al., 2011) , leading to up-regulation of nuclear factor kappa B (NF-κB) (Zwagerman et al., 2010) . NF-κB has been well-documented to be a key regulator of both cell survival and inflammatory genes (Shih et al., 2015; Harari and Liao, 2010) . NF-κB-induced inflammation has been shown to be via TLR-mediated signaling, which ultimately promotes production of proinflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) (Shih et al., 2015) .
TLRs are critical in mediating inflammation, and therefore TLRs signaling is tightly regulated (Wang et al., 2009 ). Several TLRs signaling suppressors have been described in immune cells (Liew et al., 2005) . Recent studies revealed that Tyro3, Axl, and Mer (TAM receptors) play a pivotal role in negatively regulating innate immunity via the inhibition of the TLR-mediated inflammatory response and the promotion of phagocytic clearance of apoptotic cells (Wang et al., 2009) .
Tyro3, Axl, and Mer receptors make up the TAM family of tyrosine kinase receptors which are expressed on myeloid-derived hematopoietic cells. TAM receptors have been shown to suppress TLRs signaling, thereby preventing over-stimulation (Sun et al., 2010) . One of the ligands for TAMs is Growth-arrest-specific protein 6 (Gas6), which has the highest affinity for Axl. Gas6/Axl signaling pathway has been suggested to play a critical role in various diseases and in reducing inflammation (Manfioletti et al., 1993) .
Gas6 has been shown to reduce the release of proinflammatory cytokines (Alciato et al., 2010) . TAM receptors attenuate inflammation via downstream signaling including suppressor of cytokine signaling 1 (SOCS1), SOCS3, and Twist, which inhibit both TLR and cytokinedriven immune responses (Sun et al., 2010) . In the absence of TAM
